Cargando…
Early clinical experience with the p48MW HPC and p64MW HPC flow diverters in the anterior circulation aneurysm using single anti-platelet treatment
BACKGROUND: The p64MW HPC and p48MW HPC flow diverters have reduced thrombogenicity due to hydrophilic coating. The purpose of this study was to evaluate its safety and efficacy in Mongolian patients under single antiplatelet therapy (SAPT) with prasugrel. MATERIALS AND METHODS: We performed a retro...
Autores principales: | Bhogal, Pervinder, Petrov, Andrey, Rentsenkhu, Ganbaatar, Nota, Baatarjan, Ganzorig, Erdenebat, Regzengombo, Boldbat, Jagusch, Sara, Henkes, Elina, Henkes, Hans |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178779/ https://www.ncbi.nlm.nih.gov/pubmed/34233547 http://dx.doi.org/10.1177/15910199211029503 |
Ejemplares similares
-
Initial experience with the novel p64MW HPC flow diverter from a
cohort study in unruptured anterior circulation aneurysms under dual
antiplatelet medication
por: Petrov, Andrey, et al.
Publicado: (2020) -
Coating (Coating to Optimize Aneurysm Treatment in the New Flow Diverter Generation) study. The first randomized controlled trial evaluating a coated flow diverter (p64 MW HPC): study design
por: Pierot, Laurent, et al.
Publicado: (2023) -
The p48_HPC antithrombogenic flow diverter: initial human experience using single antiplatelet therapy
por: Bhogal, Pervinder, et al.
Publicado: (2019) -
The p48MW Flow Diverter—Initial Human Experience
por: Bhogal, P., et al.
Publicado: (2019) -
Use of a p64 MW Flow Diverter with Hydrophilic Polymer Coating (HPC) and Prasugrel Single Antiplatelet Therapy for the Treatment of Unruptured Anterior Circulation Aneurysms: Safety Data and Short-term Occlusion Rates
por: Hellstern, V., et al.
Publicado: (2022)